Shares of Gelteq Ltd (NASDAQ:GELS) rose sharply in pre-market trading after the company reported positive preclinical results for its cannabinoid oral gel delivery platform.

The Melbourne-based company reported that its proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared with an existing Food and Drug Administration-approved oil-based product, according to a Tuesday announcement.

Gelteq shares jumped 50.1% to $1.25 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers

• Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 in pre-market trading. The veterinary services company filed a Certificate of Amendment on Jan. 9, increasing its authorized Class A common stock from 100 million to 700 million shares, according to a Securities and Exchange Commission filing.
• Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 in pre-market trading. The online collectibles and artwork e-commerce platform said its board approved a special cash dividend of 5 cents per share on Jan. 8, according to a filing with the Securities and Exchange Commission dated Jan. 12.
• XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 in pre-market trading, following a Securities and Exchange Commission filing and the company’s announcement of expansion financing plans.
• Jet.AI Inc (NASDAQ:JTAI) gained 20.3% to $0.48 in pre-market trading after dipping 15% on Tuesday.
• Mingteng International Corp Inc (NASDAQ:MTEN) rose 19.3% to $0.040 in pre-market trading after falling 56% on Tuesday.
• China SXT Pharmaceuticals Inc (NASDAQ:SXTC) gained 19% to $0.12 in pre-market trading. Univest Securities, LLC announced closing of $10 million registered direct offering for its client China SXT Pharmaceuticals.
• AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 in pre-market trading after the company’s director, Hongyu Zhou, bought 1.109 million shares at an average price of $1.35 per share.
• Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 in pre-market trading. Autolus Therapeutics, on Monday, announced preliminary fourth-quarter and FY25 revenue results.
• Bilibili Inc – ADR (NASDAQ:BILI) rose 5.2% to $33.03 in pre-market trading.

Losers

• Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 in pre-market trading after the company announced pricing of $30 million public offering.
• Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 in pre-market trading after jumping 19% on Tuesday.
• Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 in pre-market trading after gaining 56% on Tuesday.
• JIADE Ltd (NASDAQ:JDZG) dipped 18.5% to $0.98 in pre-market trading after jumping 54% on Tuesday.
• iOThree Ltd (NASDAQ:IOTR) declined 17.6% to $3.27 in pre-market trading after jumping 52% on Tuesday.
• AlphaTON Capital Corp (NASDAQ:ATON) shares dipped 17.6% to $1.07 in pre-market trading. AlphaTON Capital, on Tuesday, announced a $15 million registered direct offering.
• Plus Therapeutics Inc (NASDAQ:PSTV) tumbled 16% to $0.40 in pre-market trading after declining 4% on Tuesday.
• X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) fell 15.3% to $0.90 in pre-market trading. XTL Biopharmaceuticals shares jumped 57% on Tuesday after the company announced a binding agreement to acquire 85% of NeuroNOS.
• Glaukos Corp (NYSE:GKOS) fell 12.1% to $96.97 in pre-market trading. The company reported preliminary fourth-quarter and FY25 sales results.
• Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 in pre-market trading. Trip.com Group confirmed earlier report that it is under investigation by China’s SAMR for potential anti-monopoly violations.

Now Read This:

• Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Quarter

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.